Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early erythropoietin plus testosterone for traumatic neurological injury
IRCT20170105031787N5Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erythropoietin and testosterone in traumatic brain injury (TBI) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Level of consciousness, Deep venous thrombosis of the lower limb and 1 more. Started May 2022; status: completed.
02
Drugs
erythropoietintestosterone
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20170105031787N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170105031787N5.